Advancement in the development of mRNA-based vaccines for respiratory viruses

Simple item page
dc.article.number13844
dc.catalogadoraba
dc.contributor.authorTroncoso Bravo, Tays S.
dc.contributor.authorRamírez, Mario A.
dc.contributor.authorLoaiza, Ricardo A.
dc.contributor.authorRoman Cardenas, Carolina
dc.contributor.authorPapazisis, Georgios
dc.contributor.authorGarrido Cortés, Daniel
dc.contributor.authorGonzález, Pablo A.
dc.contributor.authorBueno Ramírez, Susan
dc.contributor.authorKalergis Parra, Alexis Mikes
dc.date.accessioned2025-04-01T15:33:54Z
dc.date.available2025-04-01T15:33:54Z
dc.date.issued2024
dc.description.abstractAcute respiratory infections are the leading cause of death and illness in children under 5 years old and represent a significant burden in older adults. Primarily caused by viruses infecting the lower respiratory tract, symptoms include cough, congestion, and low-grade fever, potentially leading to bronchiolitis and pneumonia. Messenger ribonucleic acid (mRNA)-based vaccines are biopharmaceutical formulations that employ mRNA molecules to induce specific immune responses, facilitating the expression of viral or bacterial antigens and promoting immunization against infectious diseases. Notably, this technology had significant relevance during the COVID-19 pandemic, as these formulations helped to limit SARS-CoV-2 virus infections, hospitalizations, and deaths. Importantly, mRNA vaccines promise to be implemented as new alternatives for fighting other respiratory viruses, such as influenza, human respiratory syncytial virus, and human metapneumovirus. This review article analyzes mRNA-based vaccines' main contributions, perspectives, challenges, and implications against respiratory viruses.
dc.description.funderFONDECYT; Folios: 190830, 1231851
dc.description.funderANID-Millenium Institute on Immunology and Immunotherapy; Folio: ANID ACE 210015 CN09_016, ICN2021_045
dc.description.funderANID; Folio: 21210336
dc.description.funderBiomedical ResearchConsortium-Chile; Folio: CTU06
dc.format.extent16 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1111/imm.13844
dc.identifier.eissn1365-2567
dc.identifier.issn0019-2805
dc.identifier.urihttps://doi.org/10.1111/imm.13844
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/103080
dc.identifier.wosidWOS:001293918400001
dc.information.autorucEscuela de Ingeniería; Troncoso Bravo, Tays S.; S/I; 1069654
dc.information.autorucEscuela de Ingeniería; Garrido Cortés, Daniel; 0000-0002-4982-134X; 226814
dc.information.autorucFacultad de Ciencias Biológicas; Bueno Ramírez, Susan; 0000-0002-7551-8088; 113541
dc.information.autorucFacultad de Ciencias Biológicas; Kalergis Parra, Alexis Mikes; 0000-0001-7622-5263; 90610
dc.issue.numero3
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final496
dc.pagina.inicio481
dc.revistaImmunology
dc.rightsacceso restringido
dc.subjectmRNA
dc.subjectRespiratory diseases
dc.subjectVaccine
dc.subjectViral infection
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAdvancement in the development of mRNA-based vaccines for respiratory viruses
dc.typeartículo de revisión
dc.volumen173
sipa.codpersvinculados1069654
sipa.codpersvinculados226814
sipa.codpersvinculados113541
sipa.codpersvinculados90610
sipa.trazabilidadORCID;2025-03-03
Files
Collections
Artículos de revistas